Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer
Completed · Phase 2
Conditions studied: Colorectal Cancer, Metastatic Cancer
In brief
RATIONALE: Vaccines made from a gene-modified virus and a person's white blood cells may make the body build an effective immune response to kill tumor cells. Biological therapies, such as Granulocyte-macrophage colony-stimulating factor (GM-CSF), may stimulate the immune system in different ways and stop tumor cells from growing. Combining different types of biological therapies may kill more tumor cells. PURPOSE: This randomized phase II trial is studying giving vaccine therapy together with dendritic cells to see how well it works compared to giving vaccine therapy together with GM-CSF in treating patients with liver or lung metastases from colorectal cancer removed by surgery.
Key facts
- Study ID
- NCT00103142
- Run by
- Michael Morse, MD
- People needed
- 74
- Starts
- 2005-02-01
- Expected to finish
- 2013-03-01
- Last updated by the study team
- 2015-10-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center — Washington D.C., District of Columbia, United States
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida — Tampa, Florida, United States
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
- Wake Forest University Baptist Medical Center — Winston-Salem, North Carolina, United States
- Providence Cancer Center at Providence Portland Medical Center — Portland, Oregon, United States
- Hollings Cancer Center at Medical University of South Carolina — Charleston, South Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.